Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes.
about
Infections in myelodysplastic syndromesThe clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes.The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing.Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge.Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.Thyroid dysfunction from antineoplastic agents.Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rashSynthesis of hapten and preparation of specific polyclonal antibody with high affinity for lenalidomide, the potent drug for treatment of multiple myelomaTrace determination of lenalidomide in plasma by non-extractive HPLC procedures with fluorescence detection after pre-column derivatization with fluorescamine.Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatmentThyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review.Lenalidomide-induced acute liver failure.Anaemia in the elderly.Pomalidomide-induced hypothyroidism.Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial.Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.Initial transfusion intensity predicts survival in myelodysplastic syndrome.Practical Strategies for Management of Lenalidomide-Associated Cytopenias in Myelodysplastic Syndromes With del(5q)
P2860
Q26859275-2D663888-1D0D-4225-B2F5-66C435EAD1ECQ33387037-C024A685-8D38-4652-B126-1B79B9D10C8FQ33398044-C326AB2C-36E5-472A-B929-870A1334BD20Q33411763-74025400-A105-4F3F-B5D5-03A07609B35CQ33675946-B980A9D1-2788-421C-B82A-FB4A99594DF9Q33707411-0C27B35E-2F1C-4FF4-8078-C62F95B8C672Q35500038-755420ED-BD50-47D7-9014-4CC8AE13A074Q36052316-BF8757E9-9EAF-47AC-863B-983833860989Q36394469-EA2A338F-0990-4824-BC38-609D01325E45Q36744385-16D7F6BD-736D-4AA9-B7C9-E61BFBF7536FQ37001825-AB11694E-81C6-49B9-A614-08BF641598F8Q37872263-5270E5DC-3539-4481-80CD-EB5576233011Q42556872-EB9A297D-4CC0-40BF-B37E-289A95E4FCCEQ43265727-CB853D66-98CF-47E5-B67C-2D09C890B36FQ47157931-765E4DBA-E578-453F-9019-40A33D8043DDQ50095638-86E66A04-38F1-4C24-B548-47D6D4BF05E5Q50280245-2EB2ED6C-C1B0-4179-A5C8-04A990DF1E74Q50481343-53683A1E-B85F-415E-9D00-250F92A28CA5Q58585580-32E621B6-985A-438C-967D-13A6987DF988
P2860
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Practical recommendations on t ...... of myelodysplastic syndromes.
@ast
Practical recommendations on t ...... of myelodysplastic syndromes.
@en
type
label
Practical recommendations on t ...... of myelodysplastic syndromes.
@ast
Practical recommendations on t ...... of myelodysplastic syndromes.
@en
prefLabel
Practical recommendations on t ...... of myelodysplastic syndromes.
@ast
Practical recommendations on t ...... of myelodysplastic syndromes.
@en
P2093
P2860
P50
P1433
P1476
Practical recommendations on t ...... of myelodysplastic syndromes.
@en
P2093
Ghulam J Mufti
Guillermo Sanz
Larry Cripe
Marie Von Lilienfeld-Toal
Richard A Wells
P2860
P304
P356
10.1007/S00277-008-0449-0
P577
2008-02-12T00:00:00Z
2008-05-01T00:00:00Z